AAPL 170.33 +0.29 (+0.17%)MSFT 108.2 +0.55 (+0.51%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)
AAPL 170.33 +0.29 (+0.17%)MSFT 108.2 +0.55 (+0.51%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)

Balance Sheet APLS Quote Apellis Pha

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 36 25 176
ShortTermInvest 0 0 0
Cash 36 25 176
AccountReceivab 0 0 0
Inventories 0 0 0
DeferredIncomeT 0 0 0
OtherCurrentAss 2 3 6
TotalCurrentAss 38 27 182
PPE 0 0 0
AccumulatedDepr 0 0 0
NetPPE 0 0 0
EquityAndOtherI 0 0 0
Goodwill 0 0 0
IntangibleAsset 0 0 0
OtherLTAssets 0 0 0
TotalNonCurrent 0 0 0
TotalAssets 38 27 182
ShortTermDebt 0 0 0
AccountsPayable 2 3 4
TaxesPayable 0 0 0
AccruedLiabilit 1 1 3
DeferredRevenue 0 0 0
OtherCurrentLia 0 0 0
TotalCurrentLia 3 4 7
Debt 0 0 26
DeferredTaxesLi 0 0 0
DeferredRevenue 0 0 0
OtherLTLiabilit 0 0 0
TotalNonCurrent 0 0 27
TotalLiabilitie 3 4 33
CommonStock 0 0 0
AdditionalPaidI 29 30 298
RetainedEarning -71 -98 -149
AccumulatedOthe 0 0 0
TotalStockholde 35 24 149
TotalLiabilitie 38 27 182
Apellis Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Apellis Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.